Keywords
pleural cancer
histopathology
immunohistochemistry
Kinshasa
How to Cite
Abstract
Introduction
Bronchopulmonary and pleural cancers represent a major public health problem worldwide. In the Democratic Republic of the Congo (DRC), few studies have focused on these pathologies, and no recent data were found in our review. The frequency and predominant histological types of bronchopulmonary cancers remain unknown.
Purpose
This study aimed to determine the histopathological profile of bronchopulmonary cancers in Kinshasa, with the goal of establishing their frequency, histological types, and levels of tissue infiltration.
Methods
This descriptive case series was conducted in Kinshasa across three histopathological laboratories: the University Clinic of Kinshasa, Nganda Hospital Centre, and the Leboma Laboratory. The study covered a 12-year period from 2012 to 2024.
Results
Bronchopulmonary cancers accounted for 1.4% of all tumoural and non-tumoural pathologies recorded during the study period. Among 182 patients, bronchopulmonary adenocarcinoma was the most common histological type (77%). Both adenocarcinomas and squamous cell carcinomas were primary lung cancers. Mesothelioma was the only primary malignancy of pleural tissue, affecting 12 patients (12%). The most affected age group comprised individuals over 60 years, followed by those aged 51–60 years.
Conclusion
Non-small cell lung carcinoma (NSCLC) was the most frequently reported cancer type in this study. Immunohistochemical markers are critical for establishing accurate differential and definitive diagnoses, particularly to distinguish NSCLC from malignant mesothelioma, which can share overlapping clinical and histological features. Our findings underscore a significant public health concern: lung and pleural cancers in Kinshasa often affect relatively young patients and are typically diagnosed at advanced, invasive stages. Treatment options remain limited, and prognosis is generally poor. There is an urgent need to strengthen early detection programmes, improve access to quality histopathological diagnosis, and raise awareness among both healthcare professionals and the general population regarding the warning signs of these cancers. Enhanced early management could substantially improve patient outcomes.
References
Bade, B. C., & Cruz, C. S. D. (2020). Lung cancer 2020: Epidemiology, etiology, and prevention. Clinics in Chest Medicine, 41(1), 1–24. https://doi.org/10.1016/j.ccm.2019.10.001
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21830
Erefai, O., Soulaymani, A., Mokhtari, A., & Hami, H. (2022, August 16). Clinical and histopathological pattern of lung cancer in Morocco. Pan African Medical Journal, 42, 283. https://doi.org/10.11604/pamj.2022.42.283.33579
Jason, et al. (2021, August 8). Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes. Clinical Cancer Research. https://aacrjournals.org/clincancerres/article-abstract/27/14/4066/671558/
Liang, B., Tong, C., Nong, J., & Zhang, Y. (2024, June 11). Histological subtype classification of non-small cell lung cancer with radiomics and 3D convolutional neural networks. Journal of Imaging Informatics in Medicine, 37(6), 2895–2909. https://doi.org/10.1007/s10278-024-00838-4
Mehta, A. A., Pavithran, K., Nair, P. K., Vazhoor, V., Gutjahr, G., & Lakshmi Priya, V. P. (2025, June 1). Epidemiological and histopathological profile of lung cancer: Insights from a 15-year cross-sectional study at a tertiary care centre in South India. Global Epidemiology, 9, 100208. https://doi.org/10.1016/j.gloepi.2025.100208
Mremi, A., Ndumbalo, J., Chuwa, H., Henke, O., & Rost, M. (2025, May 1). Lung cancer in Tanzania. Journal of Thoracic Oncology, 20(5), 560–564. https://doi.org/10.1016/j.jtho.2025.02.009
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., et al. (2022, March 1). The 2021 WHO classification of lung tumours: Impact of advances since 2015. Journal of Thoracic Oncology, 17(3), 362–387. https://doi.org/10.1016/j.jtho.2021.11.003
Perez-Moreno, P., Brambilla, E., Thomas, R., & Soria, J. C. (2012, May 1). Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. Clinical Cancer Research, 18(9), 2443–2451. https://doi.org/10.1158/1078-0432.CCR-11-2370
Pyana Kitenge, J., Kapinga Kayembe, D., Tshibangu Muamba, M., Kachil Rubing, H., De Vos, B., Van Bouwel, J., et al. (2019, September 10). Malignant mesothelioma in Sub-Saharan Africa: A case report from Lubumbashi, DR Congo. Environmental Research, 176, 108556. https://doi.org/10.1016/j.envres.2019.108556
Rindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E., et al. (2018, December 1). A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 31(12), 1770–1786. https://doi.org/10.1038/s41379-018-0110-y
Ruffini, E., Bongiovanni, M., Cavallo, A., Filosso, P. L., Giobbe, R., Mancuso, M., et al. (2004, July). The significance of associated pre-invasive lesions in patients resected for primary lung neoplasms. European Journal of Cardio-Thoracic Surgery, 26(1), 165–172. https://doi.org/10.1016/j.ejcts.2004.03.027
Sabbula, B. R., Gasalberti, D. P., Mukkamalla, S. K. R., & Anjum, F. (2025, August 12). Squamous cell lung cancer. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK564510/
Talcott, W. J., Miccio, J. A., Park, H. S., White, A. A., Kozono, D. E., Singer, L., et al. (2021, July). Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer, 157, 17–20. https://doi.org/10.1016/j.lungcan.2021.04.017
Travis, W. D., et al. (2015). WHO classification of tumours of the lung, pleura, thymus and heart (4th ed.). International Agency for Research on Cancer.
Walker-Bone, K., Benke, G., MacFarlane, E., Klebe, S., Takahashi, K., Brims, F., et al. (2023, April). Incidence and mortality from malignant mesothelioma 1982–2020 and relationship with asbestos exposure: The Australian Mesothelioma Registry. Occupational and Environmental Medicine, 80(4), 186–191. https://doi.org/10.1136/oemed-2022-108694
Zhang, K., Chen, H., Jiang, Y., Chen, Q., Su, B., & Zhou, X. (2023, June 30). Treatment options and prognosis of patients with lung squamous cell cancer in situ: A comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer. Translational Lung Cancer Research, 12(6), 1276–1292. https://doi.org/10.21037/tlcr-23-150
Zhang, Y., Vaccarella, S., Morgan, E., Li, M., Etxeberria, J., Chokunonga, E., et al. (2023, November 1). Global variations in lung cancer incidence by histological subtype in 2020: A population-based study. The Lancet Oncology, 24(11), 1206–1218. https://doi.org/10.1016/S1470-2045(23)00401-9
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.